Mean Visual Acuity Changes Following Five Injections of Aflibercept

NAActive, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetic Macular Edema
Interventions
DRUG

Aflibercept Injection [Eylea]

Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.

Trial Locations (1)

L8G 5E4

St. Joseph's Healthcare Hamilton, Hamilton

All Listed Sponsors
lead

McMaster University

OTHER

NCT02645266 - Mean Visual Acuity Changes Following Five Injections of Aflibercept | Biotech Hunter | Biotech Hunter